IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4757
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$1.0B
Vladimir Coric
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BHVN Biohaven Ltd. | 25 | 14 | 19 | 23 | - | - | -522.1% | -184.2% | - | - | - | - | 0.0% | - | $1.0B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Biohaven Ltd. (BHVN) receives a "Avoid" rating with a composite score of 25.4/100. It ranks #4757 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Moderate investment profile
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
No analyst ratings for BHVN.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 14 | 1 | +13ALPHA |
| MOMENTUM | 23 | 11 | +12ALPHA |
| VALUATION | 19 | 9 | +10ALPHA |
| INVESTMENT | 41 | 77 | -36DRAG |
| STABILITY | 30 | 16 | +14ALPHA |
| SHORT INT | 29 | 19 | +10ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC -160.4% vs WACC 8.9% (spread -169.3%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover 0.00x
Rev growth N/A, 4yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Biohaven Ltd. (BHVN) as Avoid with a composite score of 25.4/100 at a current price of $11.63. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
Biohaven Ltd. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 25.4/100 places it at rank #4757 in our full universe.
No Moat
High
Poor
Fair Value
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
Biohaven Ltd. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags Biohaven Ltd. with an Avoid rating, assigning a composite score of 25.4/100 and 1 out of 5 stars. Ranked #4757 of 7,333 stocks, BHVN falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
Biohaven Ltd. registers a weak quality score of just 14/100, indicating significant profitability challenges. The company reports a return on equity of -522.1% (sector avg: -1.9%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
BHVN registers a value score of just 19/100, suggesting the stock trades at a significant premium to its fundamental metrics. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
With an investment score of 41/100, BHVN exhibits moderate growth-oriented spending. Key growth metrics include a return on assets of -184.2% (sector: 0.9%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
Biohaven Ltd. is experiencing notably weak momentum with a score of just 23/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth data is not currently available, while a beta of 1.42 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
BHVN's stability score of 30/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.42. Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
Biohaven Ltd.'s short interest score of 29/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include above-average market sensitivity (beta: 1.42), small-cap liquidity risk. At $1.0B (small-cap), BHVN carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Biohaven Ltd. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4757 of 7,333 overall (35th percentile). Key comparisons include ROE of -522.1% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While BHVN currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Quality (14) would have the largest impact on the composite score.
ROE 27378% ABOVE SECTOR MEDIAN (FAVORABLE)
Div. Yield NaN% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Shares of Biohaven Ltd (NYSE: BHVN) fell sharply after its Phase 2 depression drug trial missed its primary endpoint. Several other companies, including Heartland Express Inc (NASDAQ: HTLD), Omeros Corp (NASDAQ: OMER), and Andersen Group Inc (NYSE: ANDG), also experienced declines in pre-market trading. This follows a mixed performance in U.S. stock futures, with Dow futures showing a slight dip.
This article analyzes Biohaven Ltd. (NASDAQ: BHVN), highlighting weak sentiment across all time horizons, supporting a short bias. It details an exceptional 112.5:1 risk-reward short setup targeting 34.5% downside against a minimal 0.3% risk. The piece also outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis.
This article provides an analysis of Biohaven Ltd. (NASDAQ: BHVN) stock dynamics, highlighting strong near- and mid-term sentiment but a weak long-term outlook. It details AI-generated institutional trading strategies including long, breakout, and risk hedging positions, along with multi-timeframe signal analysis for support and resistance levels. The report suggests a breakout is underway and offers real-time signals for positioning and risk management.
Despite a challenging 2025 marked by an FDA rejection and missed payments, Biohaven CEO Vlad Coric is optimistic about the company's future, particularly its entry into the obesity treatment market. Biohaven plans to repurpose its SMA drug, taldefgrobep alfa, as a muscle-sparing treatment for GLP-1 users, aiming to rival Lilly's bimagrumab without similar side effects. The company is well-capitalized after recent investments and boasts a diverse pipeline, including a protein degrader therapy for autoimmune conditions.
U.S. stock futures declined on Friday following Wednesday's gains, with major indices showing modest losses. Key movers included Nvidia rising on a licensing agreement with Groq, Dynavax surging 38% on Sanofi acquisition news, Sobr Safe dropping 16% after announcing a private placement, and Biohaven plummeting 14% after a failed clinical trial. Economist Justin Wolfers cautioned that U.S. market gains are lagging global markets significantly.